| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.2174/1871528113666140224103712 |
| P698 | PubMed publication ID | 24559124 |
| P2093 | author name string | Matthieu Bereau | |
| Éric Toussirot | |||
| P433 | issue | 2 | |
| P921 | main subject | progressive multifocal leukoencephalopathy | Q704930 |
| P304 | page(s) | 121-127 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | Inflammation and Allergy: Drug Targets | Q15762351 |
| P1476 | title | The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases | |
| P478 | volume | 13 |
| Q38514894 | Biologic agents in the treatment of glomerulonephritides |
| Q39705818 | Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system |
| Q38423474 | Past, present, and future for biologic intervention in atopic dermatitis |
| Q90650037 | Perspectives of Patients with Multiple Sclerosis on Drug Treatment: A Qualitative Study |
| Q37027705 | Quantitative analysis of multiple sclerosis patients' preferences for drug treatment: a best-worst scaling study |
| Q50102128 | The national incidence of PML in Sweden, 1988-2013. |
| Q34457345 | The osteopontin transgenic mouse is a new model for Sjögren's syndrome |
| Q26798434 | Treatment strategies for multiple sclerosis: When to start, when to change, when to stop? |
Search more.